Veracyte, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-81.0% vs price
Base Case (Median)
-45.6% vs price
Bull Case (75th pct.)
-13.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.59 | -89.1% | High (40%) |
| PE Comparable | $31.16 | -26.0% | Medium (25%) |
| Growth Trajectory DCF | $120.55 | 186.5% | Medium (20%) |
| Graham Number | $22.91 | -45.6% | Medium (40%) |
| EV/EBITDA | $11.40 | -72.9% | Medium (20%) |
| EV/FCF | $42.11 | 0.1% | Medium (20%) |
| Earnings Power Value | $4.57 | -89.1% | Medium (50%) |
Based on 7 out of 8 methods, VCYT appears overvalued at the current price of $42.08. The base case fair value of $22.91 implies 45.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.